Abstract 293P
Background
Venous thromboembolism (VTE) is common in patients with cancer and is associated with increased mortality. Dabigatran is effective or superior to conventional agents like warfarin or low-mol-wt-heparin (LMWH) for treating cancer-associated thrombosis (CAT). However, there is limited data outside of clinical trials, and concerns exist about the potential side effects in unselected patients.
Methods
The medical records of patients who received generic dabigatran for CAT between July 2019-July 2021 were accessed to get data on: baseline characters, nature and extent of VTE, treatment duration, and outcome.
Results
Thirty pts [median age: 34 years (8-66years), 13 males (43%), ECOG PS 0,1: 28 (93%)] with active cancer [acute lymphoblastic leuk. (N=12), non-Hodgkin's lymphoma (N=2), breast ca (N=5), gastric ca (N=3), colon ca (N=3), ovarian ca (N=2), gestational trophoblastic neoplasia (N=2), Ewing's sarcoma (n=1)] and VTE were included. Only 1/30 had a history of DVT, and 5 pts had central venous catheters (CVC). Drugs associated with thrombosis were used in 16 pts [(Bevacizumab (n=2), L-asparaginase (n=11), cisplatin, bleomycin, and tamoxifen (n=1)]. Sites of VTE: cortical venous thrombosis (CVT, N=12), CVC-associated (N=5), legs (N=8), Others (N=5)]. Dabigatran (150 mg BD) (23 after 2 weeks of LMWH, 7 upfront) was used for a median of 6 mos (3-20mos). At 4 mos, radiological response was available in 19 pts (complete resolution (N=6), partial in 8, stable in 5) and 11 had clinical improvement. Three patients had recurrent VTE after stopping dabigatran (2 pulmonary and 1 CVT). At last follow-up, 21 pts were alive, five died due to cancer, and four were lost from follow-up. Temporary stopping was needed in 3 pts (for low platelets), of which 1 had a bleeding episode.
Conclusions
Generic dabigatran is a safe, inexpensive (INR 800-1000 per month) and effective outpatient option for CAT in developing countries. Owing to its cheaper cost, ease of administration, and likely better patient compliance, dabigatran could become a potential alternative to LMWH.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - Cancer-related symptoms as mediators between treatment and functional capacity in adolescents and young adults (AYAs) with cancer
Presenter: Chung Tin Justin Ma
Session: Poster viewing 04
282P - Nutritional status and nutritional therapy of common cancer in a cancer hospital of Southwest China
Presenter: Huiqing Yu
Session: Poster viewing 04
283P - Comparative analysis of osteoporotic fracture (OF) and pathologic fracture (PF) in patients with metastatic colorectal cancer (mCRC) who received palliative chemotherapy
Presenter: Yejee Lim
Session: Poster viewing 04
284P - Gut microbiota mediates the protective effects of resveratrol against the intestinal barrier dysfunction in non-alcoholic steatohepatitis induced by high-fat diet
Presenter: Haoyang Cao
Session: Poster viewing 04
285P - Reticulocyte hemoglobin equivalent as an early predictor of iron deficiency anemia in cancer patients
Presenter: Aditya Sarin
Session: Poster viewing 04
286P - Breakthrough COVID-19 infections in patients with cancer from a prospective study of COVID-19 vaccine response
Presenter: Amy Body
Session: Poster viewing 04
287P - Long-term yoga enhances the quality of life and symptomatic scale in breast cancer patients undergoing treatment
Presenter: Mayank Jain
Session: Poster viewing 04
288P - Impact of hormonal contraception on estradiol and progesterone serum levels: A 6-year study on progression-free survival, disease-free survival, and overall survival at Dr. Moewardi Hospital
Presenter: Widyanti Soewoto
Session: Poster viewing 04
289P - Cancer cachexia following breast cancer (BC) chemotherapy was associated with clinical stage, number of chemotherapy cycles, and vitamin D concentration
Presenter: Susanna Hutajulu
Session: Poster viewing 04
290P - Use of PEG G-CSF is associated with decreased myelotoxicity in dexrazoxane-used aggressive non-Hodgkin lymphoma patients
Presenter: Sung-Nam Lim
Session: Poster viewing 04